Assertio Holdings

ASRT · NASDAQ

Price unavailable right now.

No price history for this range.

About ASRT

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The company is headquartered in Lake Forest, Illinois and currently employs 53 full-time employees. The firm has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.

Employees: 53
Headquarters: Lake Forest, Illinois
Listed: Feb 12, 1997
Sector: Health Care
Industry: Pharmaceuticals
Website: assertiotx.com

Leadership

Assertio Holdings executives
Name	Title	Since	Age
Heather Mason	—	2019	64
Paul Schwichtenberg	—	—	54
Mark Reisenauer	—	2025	60
Ajay Patel	—	—	41
Sam Schlessinger	—	—	43
Mary Pietryga	—	—	59
Sravan Emany	—	—	48
Sigurd Kirk	—	—	58
William Mckee	—	—	63
David Stark	—	—	56

Revenue by product and region

Fiscal year ended Dec 31, 2025: $118.71M total revenue

By product

Product sales, net$117.10M98.6%
Royalty revenue$1.61M1.4%

Similar companies

Companies in the same industry as Assertio Holdings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.